Sermorelin Research: GHRH(1-29)-Amide and What Published Studies Investigated

What is sermorelin?

What is sermorelin? It is a synthetic 29-amino-acid peptide corresponding to residues 1–29 of human growth-hormone-releasing hormone, carrying a C-terminal amide in place of the free acid. In the literature it is written GHRH(1-29)NH₂, or by the older name GRF(1-29)-amide. The defining fact about it is a truncation result: native human GHRH circulates as 40- and 44-residue peptides, but the receptor-activating information turned out to live almost entirely in the N-terminal end, and the 1–29 amide retains the growth-hormone-releasing potency of the full-length hormone in the assays where the two were compared.

That makes sermorelin structurally unusual among the compounds in this part of the catalogue. It is not a designed molecule in the way MK-677 is, and it is not a stabilised variant in the way tesamorelin is. It is a fragment — the minimal piece of a natural hormone that still does the job at the receptor. Everything below describes chemistry, receptor pharmacology and what investigators measured; none of it describes an effect in a reader.

Discovery and origin in the literature

Isolating the hormone (1982)

GHRH was not isolated from the hypothalamus, where it is made, but from tumours that were producing it in gross excess. In 1982 two groups reported the characterisation of a growth-hormone-releasing factor from human pancreatic tumours associated with acromegaly: Guillemin and colleagues in Science (PMID 6812220) and Rivier, Spiess, Thorner and Vale in Nature (PMID 6292724). The tumour source is the reason the early literature calls the molecule “human pancreatic GRF” rather than a hypothalamic name. Multiple chain lengths were recovered, principally a 44-residue and a 40-residue form.

Finding the active core (1984)

Structure–activity work followed immediately, and it converged on the same answer: the N-terminal region carried the activity. Lance, Murphy, Sueiras-Diaz and Coy (1984, Biochem Biophys Res Commun, PMID 6231028) worked explicitly on analogues of growth-hormone-releasing factor (1-29)-amide, establishing that scaffold as the working core for the medicinal chemistry that followed. In the same year Grossman and colleagues (Clin Endocrinol, PMID 6236914) reported responses to GHRH analogues in normal subjects and in growth-hormone-deficient children and young adults — an early human characterisation of what the fragment did to circulating growth hormone in those study populations.

The receptor (1992)

The pituitary-specific GHRH receptor was cloned and expressed by Mayo in 1992 (Mol Endocrinol, PMID 1333056), which put the mechanism on molecular footing rather than pharmacological inference. Mayo and colleagues later reviewed the regulation of the somatotroph cell by GHRH and its receptor (2000, Recent Prog Horm Res, PMID 11036940).

Reference data

The identity facts below come from the public chemical record (PubChem CID 16132413) and standard catalogue data. They describe identity and physical form only, and any field that could not be sourced has been left out rather than estimated.

Two structural notes are worth drawing out because they matter analytically. First, the single methionine at position 27 is an oxidation-prone residue, which is one of the impurity species reversed-phase HPLC is expected to resolve on a certificate. Second, there is no cysteine anywhere in the sequence, so there is no disulfide bond to scramble — a simplification relative to cyclic peptides. These are handling and analytical facts, not a preparation protocol; no reconstitution volume, concentration or route is given or implied anywhere on this page.

Mechanisms researchers have examined

The sermorelin mechanism literature is GHRH-receptor literature. Each point below is what studies characterised in model systems:

• GHRH-receptor agonism — sermorelin is described as an agonist at the growth-hormone-releasing-hormone receptor (GHRH-R), a class B G-protein-coupled receptor expressed on anterior-pituitary somatotroph cells and cloned by Mayo (1992).
• Gsα → adenylyl cyclase → cAMP → PKA — the canonical cascade characterised in GHRH biology and reviewed by Mayo et al. (2000), leading to synthesis and secretion of endogenous growth hormone by the somatotroph.
• Upstream, pituitary-level action — because the molecule acts on the pituitary rather than supplying growth hormone directly, the reviews describe the resulting secretion as remaining subject to normal hypothalamic control, including negative feedback and somatostatin tone. This is a description of where in the axis the molecule acts.
• Rapid clearance — the unmodified fragment carries no protection at the N-terminal dipeptide and is described in the literature as short-lived in circulation. This is precisely the property later analogues were engineered to change, and it is a pharmacokinetic observation rather than an outcome.
• A different receptor from the ghrelin mimetics — sermorelin does not act at GHS-R1a. That receptor is the target of GHRP-2, GHRP-6, hexarelin, ipamorelin and MK-677. The distinction is receptor identity, stated as a mechanistic contrast and not as a combination.

Research findings by area

Described strictly as what investigators set out to measure:

• Structure–activity chemistry — Lance et al. (1984) examined how substitutions on the GRF(1-29)-amide scaffold changed releasing activity, work that mapped which residues the receptor requires.
• Human secretory response — Grossman et al. (1984) measured circulating growth hormone after GHRH analogues in normal subjects and in growth-hormone-deficient children and young adults, examining whether the pituitary in those groups was able to respond to direct GHRH-receptor stimulation.
• Diagnostic and paediatric literature — Prakash and Goa (1999, BioDrugs, PMID 18031173) reviewed the accumulated data on sermorelin in the diagnosis and treatment of children with idiopathic growth hormone deficiency. That review is the single most complete survey of the compound’s clinical record, and its scope is worth noting precisely: paediatric idiopathic GHD, not adults and not body composition.
• Somatotroph regulation — Mayo et al. (2000) reviewed how GHRH and its receptor govern somatotroph proliferation and secretion, the mechanistic backdrop for all of the above.

One implication of the mechanism runs through the whole clinical literature and is stated here as the reviews state it: a GHRH-receptor agonist can only act on a pituitary that has somatotrophs able to respond. Where the deficiency is pituitary rather than hypothalamic, the target is simply not there. That is a limit of the mechanism, described as such.

Research models, regulatory history and evidence status

Sermorelin occupies an unusual position: unlike most compounds in a research catalogue it once was an approved medicine, and it is documented as having left the market. The FDA Drugs@FDA database lists GEREF (sermorelin acetate) under NDA 019863 and NDA 020443, sponsor EMD Serono, with a marketing status of Discontinued. Reported plainly, that is a regulatory record, and a marketing-status change of this kind is not in itself a statement about the molecule’s pharmacology. Material supplied for laboratory research is not the approved medicinal product, and nothing on this page suggests it is equivalent to one.

What is not established

The honest boundary is narrow and worth stating without hedging. The published human record concentrates on secretory response — did circulating growth hormone rise when the receptor was stimulated — and on a paediatric idiopathic-GHD population reviewed by Prakash and Goa. There is no substantial modern controlled literature examining sermorelin in healthy adults, no body-composition trial programme comparable to the one that exists for tesamorelin, and no long-term safety dataset in a non-deficient population. Claims commonly attached to this compound on vendor pages — anti-ageing, recomposition, sleep, recovery — are not supported by the studies cited here, and this page makes none of them. Where a compound’s reputation has outrun its literature, saying so is the accurate summary.

On anti-doping status, reported as fact and not as a use case: growth-hormone-releasing factors and their analogues, GHRH analogues included, appear under section S2 of the World Anti-Doping Agency Prohibited List and are prohibited at all times, in and out of competition.

Sermorelin among the GH-axis compounds

The clearest way to place sermorelin is as the scaffold everything else in the GHRH arm was built from. CJC-1295 is the same GHRH(1-29) backbone with substitutions that resist enzymatic degradation and, in the DAC form, an albumin-binding element; the no-DAC form is commonly called mod-GRF 1-29 for exactly that reason. Tesamorelin takes a different route to the same problem: it keeps the full 44 residues and caps the N-terminus chemically. Sermorelin is the unmodified original, and its short circulating life is the property those two molecules were designed around.

Across the receptor divide sit the ghrelin-receptor agonists — GHRP-6, GHRP-2, hexarelin, ipamorelin and the non-peptide MK-677. Vendor pages routinely blur the two families into a single “GH peptide” category; the published mechanism work does not, and treats them as separate receptors answering separate questions. This is receptor-family context only, not a protocol, a stack or a recommendation.

How to verify this compound yourself

A 29-residue peptide is verified the same way any synthetic peptide is — by two orthogonal analytical methods that appear on the per-batch Certificate of Analysis:

• HPLC purity — reversed-phase chromatography separates the target from synthesis-related impurities and reports purity as a percentage of the chromatogram. For a chain this length the relevant impurities are deletion sequences (a residue missing) and the oxidised-methionine species mentioned above.
• Mass-spec identity — the measured mass is checked against the expected ≈ 3357.9 Da. A truncated chain differs by the mass of the missing residue, so this is the check that a peptide is the sequence claimed rather than merely a pure something.
• Endotoxin and sterility — where tested, these are separate quality attributes reported in EU/mg or as a sterility result, and they are independent of chemical purity. A chemically pure peptide can still fail them.

See how to read a COA for what each line on a certificate means, how to verify peptide purity for how HPLC and mass spec fit together, and the self-serve verify tool to check the exact batch on a vial in hand.

Research-grade sourcing and verification

For laboratory research use only. Sermorelin is not held in stock; it is listed as available to order in the sourcing catalogue, with a typical lead time of two to three weeks and a quote on request. Whatever is supplied ships with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation at the lot level, because a chemistry summary is only as meaningful as the identity of the material behind it. Sourcing and identity-assurance framing only — nothing here speaks to outcomes.

Frequently asked questions

Literature cited

1. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. “Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.” Science. 1982;218(4572):585–587. PMID 6812220. pubmed.ncbi.nlm.nih.gov/6812220.
2. Rivier J, Spiess J, Thorner M, Vale W. “Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour.” Nature. 1982;300(5889):276–278. PMID 6292724. pubmed.ncbi.nlm.nih.gov/6292724.
3. Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH. “Super-active analogs of growth hormone-releasing factor (1-29)-amide.” Biochem Biophys Res Commun. 1984;119(1):265–272. PMID 6231028. pubmed.ncbi.nlm.nih.gov/6231028.
4. Grossman A, Savage MO, Lytras N, et al. “Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults.” Clin Endocrinol (Oxf). 1984;21(3):321–330. PMID 6236914. pubmed.ncbi.nlm.nih.gov/6236914.
5. Mayo KE. “Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone.” Mol Endocrinol. 1992;6(10):1734–1744. PMID 1333056. pubmed.ncbi.nlm.nih.gov/1333056.
6. Mayo KE, Miller T, DeAlmeida V, et al. “Regulation of the pituitary somatotroph cell by GHRH and its receptor.” Recent Prog Horm Res. 2000;55:237–266. PMID 11036940. pubmed.ncbi.nlm.nih.gov/11036940.
7. Prakash A, Goa KL. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs. 1999;12(2):139–157. PMID 18031173. pubmed.ncbi.nlm.nih.gov/18031173.
8. US Food and Drug Administration. “Drugs@FDA: GEREF (sermorelin acetate), NDA 019863 and NDA 020443, EMD Serono” — marketing status Discontinued. accessdata.fda.gov — NDA 019863.
9. National Center for Biotechnology Information. “PubChem Compound Summary for CID 16132413, Sermorelin.” pubchem.ncbi.nlm.nih.gov/compound/16132413 (formula, mass, CAS 86168-78-7).
10. World Anti-Doping Agency. “The Prohibited List” — section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org/en/prohibited-list.